[ASC-media] LCT granted diabetes patent across the EU
PBrooke at lctglobal.com
Fri Oct 20 03:44:36 CEST 2006
Living Cell Technologies granted diabetes patent across the EU
October 19, 2006
Living Cell Technologies (ASX:LCT) has today received confirmation of the decision by the European Patent Office to grant LCT an EU patent relating to its porcine pancreatic islet cell product for type 1 diabetes.
The patent, titled Preparation and Xenotransplantation of Porcine Islets (number 1248640) extends LCT's coverage in treating type 1 diabetic patients with its DiabeCell® product and adds to LCT's existing portfolio of US and Australasian granted patents.
The patent claims are directed to xenotransplantable compositions comprising neo-natal porcine islet cells that have been exposed to nicotinamide and optionally encapsulated in alginate.
"LCT has broad patent coverage in major geographical markets for the company's diabetes product with patents already granted in the US, New Zealand, Australia, Singapore and now Europe," said LCT Managing Director Dr Paul Tan.
"The granting of this patent is part of LCT's intellectual property strategy to support our diabetes program which includes plans for human clinical trials of DiabeCell® next year," said Dr Tan.
LCT submitted a regulatory application to the New Zealand regulator MedSafe in August for clinical trials for its DiabeCell® product for type 1 diabetes patients.
The national phase registrations of this patent extend LCT's DiabeCell® patent to 15 European countries including France, Germany, Italy and the United Kingdom.
The patent, assigned to LCT's IP holding subsidiary DiabeCell Pty Ltd, was filed in 2001 and expires in 2021.
Outlook for 2006/2007:
* Approval to start clinical trials of the DiabeCell product.
* Submission of Investigational New Drug (IND) application to the FDA for NeurotrophinCell.
* Securing of an additional Designated-Pathogen-Free pig cell manufacturing facility
LCT Managing Director - NZ
Tel: +64 9 270 7941
ptan at lctglobal.com
General Manager LCT
Tel: +61 3 9813 5501
pbrooke at lctglobal.com
About Living Cell Technologies: www.lctglobal.com.
Living Cell Technologies Ltd (ASX: LCT) is an ASX listed, vertically integrated cell therapy company, operating globally through offices in Australia, New Zealand and the United States. LCT focuses on the injection of healthy living cells to replace, repair, or regenerate diseased or damaged tissues, which does not require the use of toxic drugs to prevent rejection. The company product portfolio focuses on treatments for Huntington's disease / stroke / ALS, insulin dependent diabetes and haemophilia.
All LCT announcements may be viewed in our media and investor relations section on our website at www.lctglobal.com.
This message contains confidential information and is for the use of intended recipient(s) only. If you have received this e-mail in error you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete. The sender pbrooke at lctglobal.com therefore does not accept liability for any errors or omissions in the contents of this message, which arise as a result of e-mail transmission. If verification is required please request a hard-copy version.
Warning: Although the company has taken reasonable precautions to ensure no viruses are present in this email, the company cannot accept responsibility for any loss or damage arising from the use of this email or attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
More information about the ASC-media